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Abstract
Proton therapy dose is affected by relative biological effectiveness differently than X-ray therapies. The current clinically accepted
weighting factor is 1.1 at all positions along the depth–dose profile. However, the relative biological effectiveness correlates with the
linear energy transfer, cell or tissue type, and the dose per fraction causing variation of relative biological effectiveness along the
depth–dose profile. In this article, we present a simple relative biological effectiveness-weighted treatment planning risk assessment
algorithm in 2-dimensions and compare the results with those derived using the standard relative biological effectiveness of 1.1. The
isodose distribution profiles for beams were accomplished using matrices that represent coplanar intersecting beams. These matrices
were combined and contoured using MATLAB to achieve the distribution of dose. There are some important differences in dose
distribution between the dose profiles resulting from the use of relative biological effectiveness ¼ 1.1 and the empirically derived
depth-dependent values of relative biological effectiveness. Significant hot spots of up to twice the intended dose are indicated in some
beam configurations. This simple and rapid risk analysis could quickly evaluate the safety of various dose delivery schema.
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Introduction
The advantage of proton beam therapy over conventional
radiotherapy is an improvement in the conformality of the
energy deposition inside the patient. This improvement arises
from Bragg peak at the end of the proton range.1-3 High-density
ionization events along with low energy proton tracks result in
increased irreparable DNA damage that is the physical origin
of an enhanced biological efficiency or relative biological
effectiveness (RBE).4 The RBE can be measured by cell sur-
vival experiments or derived by biophysical models.5 Proton
radiation has been shown to be more biologically effective for
human cell killing compared with X-rays6,1 and so the standard
of practice employs a dosimetric weighting factor between 1.1
and 1.2.7-9 However because RBE correlates with track struc-
ture, it increases near the end of range, at the Bragg peak.
Relative biological effectiveness is derived from several Bragg
peaks at several depths weighted to produce a flat physical dose
with each peak contributing a pocket of densely ionizing track
structures.
Several published studies support this intuition that from the
midpoint to the distal side of spread out Bragg peak (SOBP),
the RBE increases to a maximum of as much as 3 just10-15
beyond the distal dose falloff (DDF). The RBE value increases
from 1.1 at the absorber entrance to as much as 1.6 at the
midpoint of the SOBP11 and to as much as 2.9 in the DDF.12
Carabe et al16 suggested that when RBE weighing is used, the
estimated range increases as much as 3 mm.
Variation in RBE over the SOBP could result in variations in
biological dose that are not apparent when a uniform RBE of
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1.1 is used to calculate the treatment plan. This article presents
a simple technique to enable visualization of proton biological
dose in 2-dimensions and compares that with standard proton
dose using a uniform RBE of 1.1. The isodose distribution
profiles were accomplished using matrices that represent
coplanar intersecting beams. These matrices were combined
and contoured to represent the distribution of dose using stan-
dard RBE weighting values (WRBE¼1.1) or the depth-dependent
weighting values of RBE (WRBE¼[test]).
Materials and Methods
Excel and MATLAB programs were used to construct biologi-
cal isodose distributions of an artificial proton beam using
eitherWRBE¼1.1 or the depth-dependent valuesWRBE¼[test], and
the results are compared herein. In this crude construct, the
target is assumed to be a circular disk with a 30 mm diameter
with a matching SOBP. Measurements of depth–dose profiles
taken at Indiana University Health Proton Therapy Center
(IUHPTC) by Britten et al17 were modified for this perfor-
mance test of the method for determining boundary parameters
for safe dose delivery. This data set was selected not because it
was representative of published works reporting proton RBE,
but because the data were collected in-house under standard
beam conditions used for dosimetry at IUHPTC. The Britten
tumor cell clonogenic assays were performed at 33.9, 53.9,
58.6, and 60.9 mm depths along a beam with incident energy
of 87 MeV with an SOBP of 46 mm.
The data for this test of the methodology were mathemati-
cally derived. The RBE values were scaled using a relative
depth within the 30 mm SOBP. The published data were used
to establish percentage depth positions of RBE data.
The scaled position of each point of interest within the
SOBP (X(n)) is calculated:
X ðnÞ cm ¼ X cm  ðthe depth within the original SOBP 1:4cmÞ
4:5cm
þ X ðn 1Þ
ð1Þ
where X (n  1) is the depth in cm of 90% maximum dose,
proximal end of the SOBP of interest and X is the length in cm
of the SOBP of interest. The scaling factors 1.4 and 4.5 cm
isolate the modification to within the SOBP.
Two dosimetry profiles were constructed for comparison. In
addition to the isodose profile generated using the standard
weighting factor WRBE¼1.1, a position sensitive biological iso-
dose profile was calculated using the following relationship:
DRBEðRBE ¼ ref ½16Þ ¼ DRBEðRBE ¼ 1:1Þ
1:1
 WRBE¼½test ð2Þ
where DRBEðRBE ¼ ref ½16Þ is the dose at a given point cal-
culated by weighting the physical dose (the standard biological
dose divided by 1.1) at that point by the appropriate weighting
factor derived from Britten et al WRBE¼[test]. The standard
biological dose is represented as DRBEðRBE ¼ 1:1Þ
Microsoft Excel 2013 was used to develop a matrix. Each
column of the matrix contains the values of the X-ray dose
present in y for the transverse section of the treatment object
and each row contains the values of the X-ray dose present in x
for the transverse section. Each element in the matrix repre-
sents the value of the fractional dose taken from the digital data
of the dose-depth profile.
The transverse section of the treatment object is assumed to
be a 9 cm diameter circle, and the planning target volume
(PTV) is a concentric circle with a 30 mm diameter. Thus, the
matrix transverse section is 89  89 mm2. The width of
the modeled proton beam is 30 mm and it is constructed within
the matrix with the planned orientation. The matrix is filled
manually for beam angles of 0, 90, 180, 225, 270, and
315, forWRBE¼1.1 andWRBE¼[test]. There are 12 matrices total.
The matrices prepared in Excel are uploaded to MATLAB
R2013a manually.18 The total to each cell of the matrix is
achieved by summing the contribution from each intersecting
beam. The data are then normalized to 100% at maximum dose.
After the image of the isodose distribution is captured, the
‘‘colorbar’’ is used to adjust the isodose distribution weight.
‘‘Custom’’ was selected within the color map menu to set the
maximum color indicator at the maximum dose.
Results
A simple visualization of biological dose was created using
MatLab to construct a circular PTV within a homogeneous
circular treatment target volume (TTV) in 2-dimensional space.
The standard RBE of 1.1 was assumed throughout an SOBP
that was adjusted to cover the 3.0 cm diameter PTV. This
model was used to compare a variety of beam configurations
designed to provide an even dose distribution at RBE ¼ 1.1,
planned to the 90% isodose over the PTV. These plans were
then compared with isodose profiles that would result from
applying the depth dependent, 10% survival RBE values
reported by Britten et al17 under the same conditions. Because
the SOBP extent depends on the PTV, as the SOBP extent varies
the entrance percentage dose will change and the midpoint depth
will vary. The data used to test the model were rescaled at the
entrance dose and the positions of the WRBE¼[test] according to
the methods given. It therefore does not represent empirical data
but rather an approximation used to test the method described
herein. Adjusting the values provided by Britten, the relative
dose at the entrance of a 30 mm SOBP will be 0.61 and the new
positions of WRBE¼[test] as shown in Figure 1. The biologically
weighted relative dose using the rescaled values for a 30 mm
SOBP with an incident energy of 87 MeV is compared with the
standard relative dose (WRBE¼1.1). For all plan comparisons, the
dose at the proximal edge of a PTV was normalized for each
beam as shown in Figure 1 demonstrated by the red and blue
lines overlapping.
The modeled plan represents a transverse section of a 9 cm
diameter circular TTV with a concentric PTV of 3 cm diameter,
intersected by proton beams (30 mm width, 80% to 80%). Two,
3, 4, 5, and 6 beams, with 45, 90, 135, and 180 separation,
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intersect the PTV such that their DDF is at the distal side of the
PTV with an SOBP of 30 mm (90% to 90%). The dose dis-
tributions for these beams were first calculated using the stan-
dard uniform WRBE¼1.1. The dose distributions were then
recalculated using the Britten et al’s WRBE¼[test] values for
Hep2 cells, scaled to 30 mm. These WRBE¼[test] values are
depth and energy dependent and vary along the SOBP.
When theWRBE¼[test] values are applied to the dose calcula-
tion using a 45 angle between the 2 beams, a hot spot appears
at the distal edges of both beams (Figure 2). The biological
dose at the hot spot is 100% greater than the intended dose
calculated using uniform WRBE¼1.1. About 30% excess dose
is delivered to nearly half of the treatment volume due to the
increased RBE in the second half of the SOBP. When parallel
opposed beams are used (Figure 3), this increase in RBE mid-
SOBP results in a linear band of increased dose of about 35%
mid-PTV. In this case, the distal hot spots on either side of the
PTV ‘‘box’’ are 45% greater than the planned dose based on
RBE ¼ 1.1. In general, the corrected WRBE¼[test] relative dose
in the mid-distal SOBP beam edges is between 20% and 80%
greater than the uniform WRBE¼1.1 calculated doses.
If a third field is added to the parallel opposed plan such that
the separation is 90 between the beams, the influence of the
increased RBE over the second half of the SOBP of the third
beam can be visualized readily in the increased dose through-
out the upper half of the box. The difference between the cal-
culated dose distributions indicates both an increase in the
excess dose over that produced by 2 opposing beams at the
distal periphery of the 3 beams and increased dose to more
than half of the treatment volume. For 3 beams with a 45 angle
between them, the hot spot of the correctedWRBE¼[test] relative
dose is concentrated at the distal corners. Nonetheless, the dose
to the central tissue within the PTV may be approximately 30%
greater than planned. At the hot spots, the biological dose is
70% greater than that calculated using the uniform WRBE¼1.1.
The dose distributions using a uniform WRBE¼1.1 or corrected
WRBE¼[test] have no considerable differences at the PTV
entrance. Lesser increases in dose ranging between 20% and
60% can be seen at the proximal corners.
When the angle between 3 modeled beams is 90, the hot
spot visualized when using the corrected WRBE¼[test] dose is
greater by 55% than the uniform WRBE¼1.1 dose. In general,
the dose distribution using WRBE¼[test] values is 15% to 45%
higher than the standard WRBE¼1.1 dose.
Adding a fourth field to the 45 offsets reduces the area
encompassed by the 30% dose excess, but the hot spots created
by incorporating the correctedWRBE¼[test] are 60% greater than
the dose predicted by the uniform WRBE¼1.1. In general, the
WRBE¼[test]-weighted relative dose for intersection corners are
between 15% and 55% greater than the WRBE¼1.1 dose. When
the angle between each of 4 beams is increased to 90, the
WRBE¼[test] corrected dose at the hot spots is 45% greater than
the uniformWRBE¼1.1 dose (Figure 4). A hot spot is now appar-
ent in the center of the PTV. In general, the dose distribution
using corrected WRBE¼[test] is between 10% and 40% greater
than the uniform WRBE¼1.1.
Additional fields are not effective at reducing either the
distal or central hot spots. The configurations for 5 and 6 beam
distributions (Figure 5) display corrected WRBE¼[test] hot spots,
40% to 45% greater than the uniform WRBE¼1.1 dose. In gen-
eral, the corrected WRBE¼[test] relative doses are 15% to 40%
higher than the uniform WRBE¼1.1.
Discussion and Conclusion
The current standard of practice in proton therapy clinics is to
use a biological effectiveness correction factor based on
empirical evidence8 to account for the increased RBE of proton
radiation over X-ray radiation. This weighting factor,
WRBE¼1.1, is likely not accurate for all cases where the incident
beam energy and SOBP extent may vary. Empirical evidence
would indicate a dependence of RBE on linear energy transfer
(LET) that is known to vary with depth along the proton track.
Several investigations have measured variation in RBE with
depth in a biological absorber for both in vitro10,18-26 and in
vivo,27-31 systems. Experimental conditions have used various
cell lines with differences in sampling along the SOBP, initial
beam energy, RBE calculation method, tissue type, and LET
estimation. In vitro RBE values also depend upon the survival
level at which they are measured. Variations in the values of
RBE applied to planning algorithms will influence the effective
dose distributions. The application of various published RBE
values will result in different biological dose outcomes. Clin-
icians should be judicious regarding the selection of empirical
data used to model the clinical situation when applying this
method for risk assessment. We have elected to modify the
values published by Britten et al17 for illustrative purposes in
this article, though this simple technique can be used to eval-
uate potential isodose difference plots for any appropriate
weighting factors of interest. The Britten data were selected
not because it was representative of published works reporting
proton RBE, but because the data were collected in-house
under standard beam conditions used for dosimetry at
Figure 1. The 30 mm spread out Bragg peak (SOBP) depth–dose
profiles with WRBE¼1.1 (D) and WRBE¼[test] (). Incident proton
energy 87 MeV. Points are connected by linear extrapolation.
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IUHPTC. The application of this method in a clinical setting
would require, using plan specific initial beam energies, SOBP
parameters and appropriate compensated ranges as well as
appropriate empirically derived RBE values. The calculated
parameters used herein were generated specifically for the pur-
pose of illustrating the risk assessment algorithm.
Figure 3. Isodose distribution profile of parallel opposed proton beams at 0 and 180. A, WRBE¼1.1, B, WRBE¼ref[16], and C, the difference in
isodose distribution.
Figure 4. Isodose distribution profile of 4 proton beams at 0, 90, 180, and 270. A,WRBE¼1.1, B,WRBE¼[test], and C, the difference in isodose
distribution.
Figure 2. Isodose distribution profiles of 2 proton beams with 45 of separation (0 and 315) range¼ 60 mm, spread out Bragg peak (SOBP)¼
30 mm. A,WRBE¼1.1, B,WRBE¼[test], and C, the difference in isodose distribution. The planning target volume (PTV) is 30 mm in diameter and
the transverse section is 90 mm in diameter.
NP4 Technology in Cancer Research & Treatment 15(5)
The application of weighting factors not equal to 1.1 indi-
cates hot or cold spots in the dose distribution within the target
or excessive dose to healthy tissue. The techniques developed
herein disclose some significant differences between the clini-
cally applied WRBE¼1.1 dose distributions and the dose distri-
butions that would be derived from the empirically determined
WRBE values. Variations among reported RBE values
31–33 and
between values derived from in vitro and in vivo studies rep-
resent an uncertainty in the biological dose that is being deliv-
ered clinically.
The variation in biological dose depends on the number of
proton fields and the angles between them because the
increased WRBE occurs not only at the distal falloff but also
along the SOBP. Our isodose profile figures suggest that the
increase in WRBE can result in hot spots of up to 100% of the
prescribed dose for 2 beams with 45 between them (Figure 2),
about 80% for 3 beams with 45 between them, and about 60%
for 4 beam boxes (Figure 4). In general, the least worrisome
distributions used 5 or 6 beams where the increased dose spread
out relatively evenly inside the PTV, and the increase in dose
was less than 40%. The more dangerous distributions appeared
when 2 and 3 beams were created with 45 between beams
since the hot spots concentrated in relatively small areas inside
the PTV with a dose increase of up to 80% to 100%.
What is presented is a simple method for evaluating poten-
tial risk. This method can be used to rapidly assess the risk of
any clinically planned treatment. For argument’s sake, suppose
that a maximum increase in biological dose of 25% greater
than the dose determined using the standard software
WRBE¼1.1 is clinically acceptable. Then any MATLAB-
derived distribution profiles incorporating the planned para-
meters resulting in biological doses greater than planned
þ25% should be disallowed and the plan should be adjusted
to reduce all uncertainties in biological dose to less than
+25% of WRBE¼1.1 dose.
Important factors that cannot be considered in this work
because of their complexity include the anatomical placement
and extent of the hot spot. For example, a hot spot aligned with
a particularly susceptible tissue mass may result in higher risk.
Several factors are patient and organ specific and lie outside the
scope of this work. Mitigation could be accomplished by
slightly reducing the incident beam energy for some number
of fractions as suggested by Buchsbaum et al,34 which pulls the
end-of-range back from the edge of the PTV. Fortunately,
uncertainties in patient setup and organ motion during treat-
ment also contribute to a smearing effect and probably are
responsible for preventing the potential untoward patient out-
comes that might be predicted by the results presented herein.
Although there are occasional anecdotal reports of unantici-
pated treatment-related injury to patients that implicate a pos-
sible delivery of acute punctate excess dose, no evidence
exists for systematic damage associated with current proton
therapy clinical protocols using the standard WRBE¼1.1
weighting factor.
Nonetheless, this work and the work of others8,14,17,30,35
make it clear that although we have an excellent understanding
of the dose deposition physics of charged particle irradiation,
we do not have sufficient understanding of the biological
responses to that energy absorption. Because it is the biological
response that is driving the clinical prognosis, this uncertainty
is quite compelling.
In time, this methodology could be optimized and placed
into treatment planning scenarios much like we use raw dose in
the current process. Treatment planning systems (TPSs) cur-
rently are beginning to look at biologic optimization. What we
envision as this project’s ultimate use is the real-time genera-
tion of biologic dose in a TPS that can then be modulated via
the allowance of nonlinear SOBP shape so as to make biologic
dose more homogeneous. This, in essence, means inverting the
current process of optimizing physical dose and accepting bio-
logic dose to optimize biological dose and accepting physical
dose. This would have to done over time as the work to date in
clinical radiation oncology is completely based on physical
dose. It would also require a major change in how we define
beams as we would be very unlikely to use SOBP’s designed to
have a flat physical dose as we currently do. Ultimately, the
delivery of proton treatment plans would be made up of series
of unique mixtures of pristine Bragg peaks rather than SOBPs.
In the end, the visualization of biologic dose is crucial in pro-
viding the safest possible treatment plans to patients.
Figure 5. Isodose distribution profile of 6 proton beams with 0, 90, 180, 225, 270, and 315. A, WRBE¼1.1, B, WRBE¼[test], and C, the
difference in isodose distribution.
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